12,372 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period — 353; 496 events — p=<0.0001
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
Uncomplicated Plasmodium Falciparum Malaria
Primary: PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) — 70.8; 68.4; 78.6 % ACPR PCR-adjusted
Type 2 Diabetes
Primary: Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) — 5678; 5557 [mg*min/dL]
Breast Cancer
Primary: Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll) — 8.0; 9.2 Months
Ankylosing Spondylitis
Primary: Assessment of Responders for the SpondyloArthritis International Society / ASAS 20 Response — 59.7; 60.8; 28.7 % responders — p=<0.0001
Congenital Hemophilia A
Primary: Treatment Success — 96.3 Percentage of treated bleeding events
Obstructive Sleep Apnea
Primary: AHI — 19.2; 19.3 events/hour — p=>0.05
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) — -9.1; -8.0 mmHg — p=0.205
Hepatitis C
Primary: Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12) — 87.5; 92.3 percentage of participants
Hypertension
Primary: Change in Trough Sitting Diastolic Blood Pressure (SiDBP)-Double-Blind Treatment Period — -12.1; -6.2 mmHg — p=<0.001
Sexual Dysfunction · Breast Cancer Survivors
Primary: Change of Pain Score of Female Sexual Function Index — 1.15; 1.05 units on a scale
Relapsing Multiple Sclerosis
Primary: Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall Population — 10.3 percentage of participants — p=<0.0001